Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sri-9662 is an experimental small molecule belonging to the pyrido[2,3-d]pyrimidine class. It is a synthetic lipophilic antifolate designed as an inhibitor of dihydrofolate reductase (DHFR), a key enzyme in folate metabolism and DNA synthesis. The compound has been structurally characterized in complex with human DHFR and demonstrates potential antiparasitic and anticancer properties by interfering with folate-dependent metabolic pathways. Its primary use has been as a research tool or discovery agent rather than for clinical application[1][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sri-9662.